bioRN News
Heidelberg, Juni 2026 – Mit dem Final Event von GeneNovate® am 25. Juni in der Münchner Residenz endet die dritte Runde des bundesweiten Entrepreneurship-Programms der Nationalen Strategie für gen- und zellbasierte Therapien (Nationale Strategie GCT). Im Rahmen der Abschlussveranstaltung präsentierten Wissenschaftlerinnen und Wissenschaftler aus ganz Deutschland ihre innovativen Geschäftsideen mit Potenzial für zukünftige Gesundheitslösungen und […]
read more
Universität Heidelberg: Humboldt Professorship for Leading International Researcher
Highly endowed research prize goes to Harvard scientist Mathias Lichterfeld on the proposal of Ruperto Carola In order to further strengthen Heidelberg University as an internationally recognized location of infection research, Prof. Dr Mathias Lichterfeld has been selected for an Alexander von Humboldt Professorship endowed with 7.8 million euros. Leading international academics are granted this […]
read more
ERC Advanced Grants for Researchers at Universität Heidelberg
Funding from the European Research Council for projects at Ruperto Carola and the Central Institute of Mental Health Prof. Dr Fred Hamprecht from the Interdisciplinary Center for Scientific Computing of Heidelberg University is receiving valuable funding from the European Research Council (ERC), an ERC Advanced Grant, which will support a project in the field of […]
read more
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses Paris, June 23, 2026. The European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS) without relapses in the last two years. This follows the positive opinion by the European Medicines Agency’s Committee […]
read more
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
ZURICH, SWITZERLAND – June 10, 2026 — VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, today announced that its previously announced business combination (“Business Combination”) with Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, was […]
read more
Complications after liver transplantation and leukemic niches: Heidelberg Faculty of Medicine honors outstanding early-career researchers
The Heidelberg Faculty of Medicine at Heidelberg University presented the Anita and Friedrich Reutner Prize for Medical Research and the Hoffmann-Klose Prize for an outstanding Clinician Scientist project at this year’s Faculty Day – an event bringing together students, researchers, and teaching staff. The award recipients, Christine Zhang-Hagenlocher and Kristina Müller, are early-career physician-scientists From […]
read more
The Heidelberg and Mannheim University Hospitals consortium has taken first place in the Stern hospital rankings
For the first time in 14 years, there has been a change at the top of the hospital rankings, which are published annually by the MINQ Institute in collaboration with Stern. In its very first year of existence, the Heidelberg and Mannheim University Hospitals Consortium has taken first place. More information in German below: Zusammen […]
read more
CELASC 2026 presentation: Impact of topical lidocaine-prilocaine analgesia on pain-induced grooming after ear notching of mice
Finnish animal welfare legislation (Government Decree 1165/2023) effective as of January 1, 2024, requires establishments to apply “appropriate pain relief” in association with ear notching identification method of laboratory rodents(1). However, there is a lack of scientific evidence whether the benefits of applying analgesia outweigh the additional stress related to handling and drug administration. Our […]
read more
PEPperPRINT Secures State Funding for Development of GlycoPlex Glycopeptide Array Platform
Heidelberg, 15th of May 2026 – PEPperPRINT GmbH has successfully secured additional research and development funding from the innovation funding program “Invest BW” of the German state of Baden-Württemberg for the development of its new GlycoPlex platform, a high-throughput technology for disease-relevant glycopeptide analyses. The funded project, titled “GlycoPlex – High-Throughput Platform for Disease-Relevant Glycopeptide Analyses”, […]
read more
